

Halpenny Anaesthetist Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 November 2025

Halpenny Anaesthetist Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Statement of Financial Position	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 9

Halpenny Anaesthetist Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 November 2025

The directors made the following statement in respect of the unaudited financial statements:

"General responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Directors' declaration on unaudited financial statements

In relation to the financial statements which comprise the Statement of Financial Position, the Statement of Changes in Equity and the related notes:

The directors approve these financial statements and confirm that they are responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The directors confirm that they have made available to Moore, (Reporting Accountants), all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The directors confirm that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 30 November 2025."

Signed on behalf of the board

Michele Halpenny
Director

23 February 2026

Gavan Ferguson
Director

23 February 2026

Halpenny Anaesthetist Limited

STATEMENT OF FINANCIAL POSITION

as at 30 November 2025

	Notes	2025 €	2024 €
Non-Current Assets			
Property, plant and equipment	7	12,902	19,354
Current Assets			
Receivables	8	134,121	156,210
Cash and cash equivalents		1,815,899	1,630,696
		1,950,020	1,786,906
Payables: amounts falling due within one year	9	(58,995)	(68,510)
Net Current Assets		1,891,025	1,718,396
Total Assets less Current Liabilities		1,903,927	1,737,750
Equity			
Called up share capital presented as equity		20	20
Retained earnings		1,903,907	1,737,730
Equity attributable to owners of the company		1,903,927	1,737,750

We as Directors of Halpenny Anaesthetist Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 23 February 2026 and signed on its behalf by:

Michele Halpenny
Director

Gavan Ferguson
Director

Halpenny Anaesthetist Limited
STATEMENT OF CHANGES IN EQUITY

as at 30 November 2025

	Called up share capital €	Retained earnings €	Total €
At 1 December 2023	20	1,516,815	1,516,835
Profit for the financial year	-	220,915	220,915
At 30 November 2024	20	1,737,730	1,737,750
Profit for the financial year	-	166,177	166,177
At 30 November 2025	20	1,903,907	1,903,927

Halpenny Anaesthetist Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 November 2025

1. General Information

Halpenny Anaesthetist Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 504241. The registered office of the company is 31 St. Helens Road, Booterstown, Dublin, A94 Y188. The principal activity of the company is the operation of a Medical Practice.

There has been no significant change in these activities during the financial year ended 30 November 2025. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 November 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.

Revenue

Turnover represents the total value of services provided by the company, exclusive of value added tax where applicable.

Property, plant and equipment and depreciation

Property, plant and equipment are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of property, plant and equipment, less their estimated residual value, over their expected useful lives as follows:

Motor vehicles	-	12.5% Straight line
----------------	---	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other receivables

Trade and other receivables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Statement of Financial Position bank overdrafts are shown within Payables.

Trade and other payables

Trade and other payables are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Halpenny Anaesthetist Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 November 2025

Employee benefits

The company has no employees other than the director.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Statement of Financial Position date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Significant accounting judgements and key sources of estimation uncertainty

The preparation of these financial statements requires management to make judgements, estimates and assumptions that effect the application of policies and reported amounts of assets and liabilities, income and expenses.

Judgements and estimates are continually evaluated and are based on historical experiences and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

(a) Establishing useful economic lives for depreciation purposes of tangible fixed assets

The annual depreciation charge depends primarily on the estimates useful economic lives of each type of asset and estimates of residual values. The directors regularly review asset useful economic lives and change them as necessary to reflect current thinking on remaining lives in light of prospective economic utilisation and physical condition of the assets concerned. Changes in asset useful lives can have a significant impact on depreciation and amortisation charges for the period. Detail of useful economic lives is included in the accounting policies.

4. Operating profit	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation of property, plant and equipment	6,452	6,452
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including directors, during the financial year was 1, (2024 - 1).

	2025	2024
	Number	Number
Clinical Staff	1	1
	<u> </u>	<u> </u>

Halpenny Anaesthetist Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 November 2025

6. Tax on profit	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 6 (b))	<u>45,656</u>	<u>52,559</u>
(b) Factors affecting tax charge for the financial year		
The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:		
	2025 €	2024 €
Profit taxable at 12.50%	<u>211,833</u>	<u>273,474</u>
Profit before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	<u>26,479</u>	34,184
Effects of:		
Depreciation in excess of capital allowances for period	<u>807</u>	807
Close company surcharge	<u>18,370</u>	<u>17,568</u>
Total tax charge for the financial year (Note 6 (a))	<u>45,656</u>	<u>52,559</u>
7. Property, plant and equipment	Motor vehicles €	Total €
Cost or Valuation		
At 1 December 2024	<u>51,614</u>	<u>51,614</u>
At 30 November 2025	<u>51,614</u>	<u>51,614</u>
Depreciation		
At 1 December 2024	32,260	32,260
Charge for the financial year	<u>6,452</u>	<u>6,452</u>
At 30 November 2025	<u>38,712</u>	<u>38,712</u>
Carrying amount		
At 30 November 2025	<u>12,902</u>	<u>12,902</u>
At 30 November 2024	<u>19,354</u>	<u>19,354</u>
8. Receivables	2025 €	2024 €
Trade receivables	<u>70,410</u>	85,851
Taxation	<u>63,711</u>	<u>70,359</u>
	<u>134,121</u>	<u>156,210</u>

Halpenny Anaesthetist Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 November 2025

9. Payables	2025	2024
Amounts falling due within one year	€	€
Taxation	49,219	56,115
Directors' current accounts (Note 11)	5,446	8,065
Accruals	4,330	4,330
	<u>58,995</u>	<u>68,510</u>

10. Income Statement

	2025	2024
	€	€
At 1 December 2024	1,737,730	1,516,815
Profit for the financial year	166,177	220,915
	<u>1,903,907</u>	<u>1,737,730</u>
At 30 November 2025	1,903,907	1,737,730

11. Directors' remuneration and transactions

	2025	2024
	€	€
Remuneration	80,000	80,015

The following amounts are repayable to the directors:

	2025	2024
	€	€
Michele Halpenny	5,446	8,065

12. Related party transactions

There are no related party transactions which require separate disclosure in the financial statements.

13. Controlling interest

Michele Halpenny and Gavan Ferguson are considered to be the ultimate controlling parties.

14. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 23 February 2026.